News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

MDS Pharma Services (MDZ) Expands Drug Discovery Capability in Asia

6/8/2009 9:58:36 AM

KING OF PRUSSIA, PA, June 8 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, today announced that a renovation and expansion of its discovery pharmacology operation in Taiwan is under way to serve the growing global demand for work performed in Asia.

The renovation and expansion, which will be completed in 2010, is aligned with the new MDS Pharma Services strategic focus on Early Stage operations - Discovery through Phase IIa proof-of-concept services, and its commitment to serve clients in an important emerging market.

The Taiwan facility supports both molecular screening and profiling, as well as in vivo safety and efficacy testing, and the renovation plan calls for significant expansions and upgrades in each area. In vivo capacity has been doubled, and will include dedicated space tailored to individual client needs. Furthermore, the site's automated molecular screening and profiling capability and efficiency will be improved with additional robotic high-throughput screening capacity and analytical support.

"This new and expanded facility will cement our position as the global leader in the discovery pharmacology space, where we are one of the top two providers of molecular screening, and a key supplier of in vivo efficacy and safety testing," said MDS Pharma Services President David Spaight. "This investment builds on a 40-year track record of success in this service area, and supports our recently announced strategic focus on the Discovery through Phase IIa Proof-of-Concept segment of the outsourcing market."

The Taiwan site is part of MDS Pharma Services' Pharmacology/DMPK line of service, which offers molecular, cellular, ADME/DMPK and in vivo assays for use in identifying lead drug candidates, profiling for selectivity, determining potential for adverse events, evaluating efficacy and establishing proof of concept. To help speed lead optimization earlier in the discovery phase and streamline the surest path to the clinic, the Taiwan facility offers extensive capabilities in molecular and cellular pharmacology, including more than 800 assays, multiple assay methodologies, high-throughput screening with robotic automation, and expert assay development.

To view the extensive catalog of discovery assays, visit the MDS Pharma Services' Pharmacology/DMPK Website at

More Information

Additional background materials pertaining to MDS Pharma Services new strategic focus on Early Stage Operations (Discovery through Phase IIa) can be found on MDS Inc.'s Website at

About MDS Pharma Services

MDS Pharma Services, a business unit of MDS Inc., is committed to delivering quality service on-time. We offer a full spectrum of resources to meet the drug-discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, Phases I-IIa) and bioanalysis through to global clinical development (Phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at

About MDS Inc.

MDS Inc. , a global life-sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

CONTACT: MEDIA: Charlene McGrady, (610) 239-7900, ext. 231,; INVESTORS: Kim Lee, (905) 267-4230,

Read at

comments powered by Disqus